News - Page 165 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company’s First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company’s First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

Post published:July 13, 2021
Post category:Press Release

Read more about the article Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore

Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore

Post published:July 12, 2021
Post category:Press Release

Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD

Post published:July 12, 2021
Post category:Press Release

Read more about the article Psychedelic Bulletin: Compass Announces New Collaboration; MindMed Partners with Real-World Data Provider; Yale Researchers Show Psilocybin Increases Nueronal Connections

Psychedelic Bulletin: Compass Announces New Collaboration; MindMed Partners with Real-World Data Provider; Yale Researchers Show Psilocybin Increases Nueronal Connections

Post published:July 9, 2021
Post category:Psychedelic Bulletin

Read more about the article MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company

MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company

Post published:July 8, 2021
Post category:Press Release

Read more about the article Cybin Expands to Europe and Provides Update on Intellectual Property Portfolio

Cybin Expands to Europe and Provides Update on Intellectual Property Portfolio

Post published:July 8, 2021
Post category:Press Release

Read more about the article Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer

Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer

Post published:July 7, 2021
Post category:Press Release

Read more about the article Awakn Establishes Separate Preclinical and Clinical Expert Advisory Boards to Optimize Delivery of Its Expanding Development Pipeline

Awakn Establishes Separate Preclinical and Clinical Expert Advisory Boards to Optimize Delivery of Its Expanding Development Pipeline

Post published:July 7, 2021
Post category:Press Release

Read more about the article Mindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved Safety in Head-to-Head Comparison to Psilocybin for its First Lead Clinical Candidate, MSP-1014

Mindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved Safety in Head-to-Head Comparison to Psilocybin for its First Lead Clinical Candidate, MSP-1014

Post published:July 7, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary Formulations

Tryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary Formulations

Post published:July 7, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.